Gene Therapy to Improve Wound Healing in Patients With Diabetes

Diabetes Clinical Trial

Official title:

Growth Factor Gene Therapy for Wound Healing

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00065663
• Other study ID #: NIAMS-093
• Secondary ID: R44AR046154
• Status: Completed
• Phase: Phase 1
• First received: July 30, 2003
• Last updated: November 16, 2007
• Start date: August 2002
• Est. completion date: December 2004

Study information

• Verified date: November 2007
• Source: Tissue Repair Company
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Patients with diabetes may develop chronic wounds that respond poorly to treatment. Gene therapy with the platelet-derived growth factor-B gene has been shown to help with the healing of chronic wounds. This study will evaluate a new way to deliver the gene to the wound tissue.

Description:

Chronic wounds, such as diabetic ulcers, pressure ulcers, and venous stasis ulcers, cause significant morbidity in millions of patients each year in the United States. Individuals with long-standing diabetes develop both peripheral vascular disease and peripheral neuropathy. These patients may not feel pressure from shoes or objects which can damage their skin. Once a wound is formed, it may heal very slowly or not at all due to diabetic complications.

Platelet-derived growth factor-B (PDGF-B) has been approved for use in diabetic ulcers. However, delivery and maintenance of the drug at the wound site in sufficient quantities for a sufficient period of time is a major hurdle to widespread use.

Gene activated matrix (GAM) technology offers the opportunity to place a therapeutic gene contained within a structural matrix into a wound site. This study will evaluate the safety and potential clinical utility of topical applications of GAM501, a gene for PDGF-B contained within an E1-deleted adenoviral vector and formulated in a bovine type I collagen gel. This formulation allows for the migration of wound repair cells into the structural matrix, where they encounter the viral vector and subsequently produce the therapeutic protein within the local wound environment.

Participants in this study will receive up to four treatments with GAM501. Participants will be followed by multiple observations over a 6 to 7 month period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: December 2004
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

• Adequately controlled diabetes mellitus (type I or II) as defined by HbA1c < 10.0%

• Cutaneous, lower extremity, plantar medial or lateral surface ulcer between 1 and 10 cm2 post-debridement

• Ulcer present for > 6 weeks prior to study entry

• Ulcer free of all necrotic and infected soft tissue

• Affected limb transcutaneous oxygen pressure (TcpO2) > 30 mmHg at screening or a palpable dorsal pedal or posterior tibial pulse

• Inability to perceive 10 grams pressure using a Semmes-Weinstein 5.07 monofilament in the peri-ulcer area

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes
• Diabetic Foot
• Diabetic Foot Ulcers
• Foot Wounds
• Wounds and Injuries

Intervention

Genetic:
• GAM501

Locations

Country	Name	City	State
United States	Foot and Ankle Medical Center	Phoenix	Arizona
United States	University of California, San Diego	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
Tissue Repair Company

Country where clinical trial is conducted

United States, 

External Links

•   Tissue Repair Company Website